Patient Education References
1) Annals of Allergy, Asthma, & Immunology, Vol. 81, Sept. 1998, P. 203.
2) Arch Pediatr Adolesc Med / Vol.156, Oct. 2002.
3) Togias A. Allergy 1999; 54. Suppl 57, 94-105.
4) Jacobsen L, et al. Allergy 2002; 57 (s73): 23.
5) Simons FER. J Allergy Clin Immunol 1999; 104: 534-540.
6) Bousquet J, et al. J Allergy Clin Immunol 1998; 102: 558-562.
7) Malling H-J, et al. J Investig Allergol Clin Immunol 2006; 16 (3): 162-168.
8) Durham SR, et al. J Allergy Clin Immunol 2006; 117: 802-809.
9) Pajno GB, et al. Clin Exp Allergy 2001; 31 1392-1397.
10) Möller C, et al. J Allergy Clin Immunol 2002; 109:251-256.
11) Novembre E, et al. J Allergy Clin Immunol 2004; 114: 851-857.
12) Niggemann B, et al. Allergy 2006; 61 (7): 855-859.
13) Jacobsen L, et al. Allergy 1997; 52: 914-920.
14) Durham SR, et al. N Engl J Med1999; 341 (7): 468-475.
15) Hedlin G, et al. J Allergy Clin Immunol 1995; 96: 879-885.
16) Mosbech H, et al. Allergy 1988; 43 (7): 523-529.
17) Di Rienzo V, et al. Clin Exp Allergy 2003; 33: 206-210.
18) Dahl R, et al. J Allergy Clin Immunol 2006; 118: 434-440.
19) Dahl R, et al. Allergy 2006; 61: 185-190.
20) Wilson DR, et al. Allergy 2005; 60: 4-12.
FTC IT Information:
21) Internal ALK-Abelló, Inc. estimate based on market research, AAAAI. The Allergy Report: Science Based Findings on the Diagnosis & Treatment of Allergic Disorders, 1996-2001; 12 Million have been properly diagnosed, Only 2 Million are receiving appropriate IT treatment.
Quality Brochure/Extract Manufacturing References:
22) Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475.
23) Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993; 91(3):709-22.
24) Nanda A, O’Connor M, Anand M, Dreskin SC, Zhang L, Hines B, Lane D, Wheat W, Routes JM, Sawyer R, Rosenwasser LJ, Nelson HS. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol. 2004; 114(6):1339-44.
25) Schaffer N, Molomut N, Center JG. Studies on allergenic extracts. I a new method for the preparation of mold extracts using synthetic medium. Ann Allergy 1959; 17: 380-384.
26) van Ree, R. Indoor Allergens: Relevance of major allergen measurements and standardization. J Allergy Clin Immunol. 2007 Feb;119(2):270-7.
27) Lowenstein H. Quantitative immunoelectrophoretic methods as a tool for the analysis and isolation of allergens. Prog Allergy. 1978; 25:1-62.
28) Oliver JD, Henderson RE, Hauck PR. Comparison of 8 consecutive production lots of standardized cat pelt extracts. J Allergy Clin Immunol. 1992; 95(1),S81.
29) “Controlled studies demonstrate that the content of particular allergens in vaccines can be used to predict a therapeutic dose for those allergens, particularly when the vaccines are standardized. Effective doses have been determined for dust mite, cat allergen, grass, and short ragweed…The ranges of therapeutically effective doses (in micrograms, allergy units, bioequivalent allergy units, and weight per volume) are presented…” Practice Parameters for Allergen Immunotherapy - Ann Allergy 2003; 90:S1-540.
30) “Quantification of major allergens may be used to define allergen doses for effective immunotherapy. There is good evidence from immunotherapy studies with ragweed, grass, mite, cat, and venom allergens that a maintenance dose of 5-20 ug of major allergen per injection is associated with significant improvement in patient symptom scores.” WHO Position paper – Allergen Immunotherapy: therapeutic vaccines for allergic disease. Allergy 53, Suppl. 44, 1998.
31) Nelson H.S. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol. 2000; 106:41-45.
32) Plunkett G., Noieam N, Gaswint J, Lankow R. Major Allergen Content of Standardized Mite and Grass Allergenic Extracts. J Allergy Clin Immunol. 2005;115(2), S163.
33) Helm RM, Gauerke MB, Baer H, Lowenstein H, Ford A, Levy DA, Norman PS, Yunginger JW. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol. 1984; 73(6):790-800.
34) Turkeltaub, PC. Biological standardization. Arb Paul Ehrlich Institut. 1997; 91:145 156.
35) van Ree R, van Leeuwen WA, Bulder I, Bond J, Aalberse RC. Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. J Allergy Clin Immunol. 1999; 104(6):1223-30.
36) Nelson RP Jr, DiNicolo R, Fernandez-Caldas E, Seleznick MJ, Lockey RF, Good RA. Allergen-specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects. J Allergy Clin Immunol. 1996; 98(2):258-63.
37) Illi S, von Mutius E. House-dust mite allergen exposure and the development of asthma in children. Ann Allergy Asthma Immunol. 2003 Jan; 90(1):6-7.
38) Hales BJ, Martin AC, Pearce LJ, Laing IA, Hayden CM, Goldblatt J, Le Souef PN, Thomas WR. IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol. 2006; 118(2):361-7. Epub 2006 May 19.
39) Anderson MC, Baer H. Antigenic and allergenic changes during storage of a pollen extract. J Allergy Clin Immunol. 1982; 69:3-10.
40) Nelson HS. Effect of preservatives and conditions of storage on the potency of allergy extracts. J Allergy Clin Immunol. 1981; 67:64-69.
41) Plunkett G. Stability of major allergen proteins in extract mixes diluted in human serum albumin (HSA), normal saline (NSP), or glycerin (GLY). J Allergy Clin Immunol. 2007; 119(1), S105.
41) Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol. 1996; 98:382-8.
Data from some references cited above were based on studies performed with products other than those manufactured by ALK-Abelló, Inc.